Total RNA sequencing of LOUCY and SUP-T1 cell lines after treatment with Decitabine (3 days) or GSK3685032 (3 and 7 days)
Ontology highlight
ABSTRACT: Decitabine have a known DNA demethylating activity but also cause cytotoxicity through DNA damage. The two differing mechanisms of action confound studies investigating the effect of DNA demethylation in cancer treatment. The novel DNA methyltransferase 1 specific inhibitor GSK-3685032 causes loss of DNA methylation without DNA damage and offers the promising possibility to examine the molecular consequences of global loss of DNA methylation. To examine the transcriptional effect of global loss of methylation we performed total RNA sequencing of LOUCY and SUP-T1 cells treated with 10 nM Decitabine for 3 days or 300 nM of GSK3685032 for 3 and 7 days.
INSTRUMENT(S): NextSeq 2000
ORGANISM(S): Homo sapiens
SUBMITTER:
PROVIDER: E-MTAB-14375 | biostudies-arrayexpress |
SECONDARY ACCESSION(S): ERP163349
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA